ADA 2022 Wrap Up: Iterative Progress On Glucose Control, No Big Surprises

The major players in the diabetes tech sector announced new and re-hashed old clinical data at this year’s American Diabetes Association Scientific Sessions in New Orleans.  

• Source: Shutterstock

Diabetes conferences rarely include shock announcements, and this year’s American Diabetes Association Annual Scientific Sessions, held in New Orleans, proved as such. 

Any uncertainty was quashed well before the conference. On May 31, Dexcom refuted a rumor founded in a May...

More from Diabetic Care

More from Device Area

Former Top OIG Attorney Gives Inside Look At Fraud Prevention

 
• By 

Former HHS-OIG attorney Rob DeConti emphasized the significance of data analytics and compliance in combating healthcare fraud, urging medical tech companies to adopt robust measures to prevent potential risks.

Deaths And Serious Injuries Linked To A Pair Of Heart Device Recalls

 

Two recent recalls from the US FDA involve three deaths linked to an issue with an Abiomed heart pump — as well as three serious injuries related to angiographic catheters from Cook Medical.

‘Be Quick, But Don’t Hurry’: Dexcom CEO Talks CGM Market Success

 
• By 

Dexcom’s CEO Kevin Sayer discusses this fall’s planned launch of the 15-day G7 CGM, downplays Abbott’s dual-sensor while focusing on development of multi-analyte G8, making OTC Stelo app more “consumerish” for Europeans, and more.